Next Article in Journal
Antinociceptive Activity of Macaranga denticulata Muell. Arg. (Family: Euphorbiaceae): In Vivo and In Silico Studies
Previous Article in Journal
Systematic Overview of Bacopa monnieri (L.) Wettst. Dominant Poly-Herbal Formulas in Children and Adolescents
Article Menu

Export Article

Open AccessReview
Medicines 2017, 4(4), 87; https://doi.org/10.3390/medicines4040087

Mesenchymal Stromal Cells for Antineoplastic Drug Loading and Delivery

1
Department of Thoracic Surgery, European Institute of Oncology, 20141 Milan, Italy
2
Department of Oncology and Hemato-oncology, University of Milan, 20141 Milan, Italy
3
Department of Farmaceutical Sciences, University of Milan, 20141 Milan, Italy
4
Department of Radiology, European Institute of Oncology, 20141 Milan, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Gerhard Litscher
Received: 4 November 2017 / Revised: 22 November 2017 / Accepted: 22 November 2017 / Published: 23 November 2017
Full-Text   |   PDF [999 KB, uploaded 24 November 2017]   |  

Abstract

Mesenchymal stromal cells are a population of undifferentiated multipotent adult cells possessing extensive self-renewal properties and the potential to differentiate into a variety of mesenchymal lineage cells. They express broad anti-inflammatory and immunomodulatory activity on the immune system and after transplantation can interact with the surrounding microenvironment, promoting tissue healing and regeneration. For this reason, mesenchymal stromal cells have been widely used in regenerative medicine, both in preclinical and clinical settings. Another clinical application of mesenchymal stromal cells is the targeted delivery of chemotherapeutic agents to neoplastic cells, maximizing the cytotoxic activity against cancer cells and minimizing collateral damage to non-neoplastic tissues. Mesenchymal stem cells are home to the stroma of several primary and metastatic neoplasms and hence can be used as vectors for targeted delivery of antineoplastic drugs to the tumour microenvironment, thereby reducing systemic toxicity and maximizing antitumour effects. Paclitaxel and gemcitabine are the chemotherapeutic drugs best loaded by mesenchymal stromal cells and delivered to neoplastic cells, whereas other agents, like pemetrexed, are not internalized by mesenchymal stromal cells and therefore are not suitable for advanced antineoplastic therapy. This review focuses on the state of the art of advanced antineoplastic cell therapy and its future perspectives, emphasizing in vitro and in vivo preclinical results and future clinical applications. View Full-Text
Keywords: drug loading; drug delivery; mesenchymal stromal cell; paclitaxel drug loading; drug delivery; mesenchymal stromal cell; paclitaxel
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Petrella, F.; Rimoldi, I.; Rizzo, S.; Spaggiari, L. Mesenchymal Stromal Cells for Antineoplastic Drug Loading and Delivery. Medicines 2017, 4, 87.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top